Micro Cap Surging On Company Developed CCR5 Antagonist Showing Promise In Patients

Sponsored:

Monday, February 24, 2025

Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer that has already spread beyond the breast and lacks estrogen, progesterone, and HER2 receptors, making it difficult to treat with hormone or targeted therapies. This form of cancer tends to grow and spread quickly, with limited treatment options primarily focused on chemotherapy, immunotherapy, and clinical trials. With these morbid stats, its always promising when news hits of positive developments against this aggressive disease.

Today, shares of CytoDyn Inc. (OTCQB: CYDY) are on a tear as the biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced encouraging survival outcomes among a group of patients with metastatic triple-negative breast cancer treated with leronlimab. 

Although mTNBC typically has a poor prognosis, observed survival rates at 12, 24, and 36 months after treatment with leronlimab compare favorably with reported life expectancy after treatment with currently approved therapies. 

In addition, the Company confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease.

“We are encouraged by the longer-term survival data to pursue this potentially paradigm-shifting therapeutic pathway for patients suffering from metastatic triple-negative breast cancer,” said Richard Pestell, MD, PhD, AO, the Company’s Lead Consultant in Preclinical and Clinical Oncology.

Dr. Jacob Lalezari, CEO of CytoDyn, added: “These provocative observations of improved survival in patients with mTNBC and prior treatment failure in the metastatic setting, including reported clearance of disease in a group of long-term survivors, provides early clinical evidence of leronlimab’s potential impact in the treatment of TNBC and other solid tumors. I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”

As mentioned off the top, shares of CYDY are surging on this news, currently up 35.46% at $0.4049 on very strong volume as investors cheer on the prospects for leronlimab.

Sponsored: